^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody

Company:
Roche
Type:
FDA Approved
Related tests:

Details

Evidence
The VENTANA MMR IHC Panel is a qualitative immunohistochemistry (IHC) test intended for use in the light microscopic assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6) and BRAF V600E proteins in formalin-fixed, paraffin-embedded colorectal cancer (CRC) tissue sections. The VENTANA MMR IHC Panel includes VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody, VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody, and VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody. It is is indicated in patients diagnosed with colorectal cancer (CRC) to detect mismatch repair (MMR) proteins deficiency as an aid in the identification of probable Lynch syndrome and to detect BRAF V600E protein as an aid to differentiate between sporadic CRC and probable Lynch syndrome.
Cancer:
Colorectal Cancer
Gene:
MSH2 (MutS Homolog 2)
Method:
Immunohistochemistry (IHC)
Approvals
Date
Cancer
Gene
Drug
By
10/27/17
FDA